期刊
EXPERT REVIEW OF VACCINES
卷 6, 期 5, 页码 761-772出版社
FUTURE DRUGS LTD
DOI: 10.1586/14760584.6.5.761
关键词
adjuvant; antibody; immunotherapy; ISCOMATRIX; t-cell; vaccine
类别
The ISCOMATRIX (TM) adjuvant has antigen-delivery and -presentation properties, as well as immunomodulatory capabilities that combine to provide enhanced and accelerated immune responses. The responses are broad, including a range of subclasses of antibodies as well as both CD4(+) and CD8(+) T cells. A range of ISCOMATRIX vaccines (ISCOMATRIX adjuvant combined with antigen) have been evaluated in clinical trials. The results of these completed and ongoing studies indicate that the ISCOMATRIX adjuvant is safe and generally well tolerated and increases the vaccine immune responses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据